Biomerieux Japan LTD.

Biomerieux Japan LTD. is a Japanese subsidiary of Biomerieux SA, a France-based global biotechnology company specializing in in vitro diagnostics and microbiological testing systems. Registered in SAM.gov since September 20, 2023, the entity operates as a corporate, for-profit organization and provides specialized laboratory diagnostic equipment, consumable supplies, and maintenance services to the U.S. federal government. The company serves the Defense Health Agency by supplying mission-critical microbiological analyzer systems and related products to forward-deployed U.S. military medical treatment facilities in the Pacific region, with a particular focus on supporting Naval medical installations in Japan.

Biomerieux Japan LTD. has received three prime federal contract awards from the Defense Health Agency, all issued as purchase orders with completion dates extending through September 30, 2027, and all carrying no set-aside designations. The company has provided VITEK 2 test card consumables, including specific product lines designated AST-GP67, AST-N809, and AST-ST02, which are used for antimicrobial susceptibility testing of bacterial and fungal pathogens in clinical microbiology laboratories. Additionally, the vendor has supplied reagents and consumable supplies for existing Biomerieux Vitek 2 Compact Analyzer systems and preventive maintenance services for both VITEK 2 Compact Analyzers and BACT 3D0120 Virtuo analyzers at U.S. Naval Hospital Yokosuka and Branch Health Clinic Iwakuni. These three contracts, valued at $238,738.38 in aggregate, represent sole-source and direct procurement arrangements that enable the Defense Health Agency to maintain critical laboratory diagnostic capabilities at overseas military medical facilities, ensuring reliable diagnostic equipment functionality for Navy Medicine personnel and eligible beneficiaries stationed in Japan.